Toufik Abdul-Rahman, Ileana Lizano-Jubert, Zarah Sophia Blake Bliss, Neil Garg, Emily Meale, Poulami Roy, Salvatore Antonio Crino, Bethineedi Lakshmi Deepak, Goshen David Miteu, Andrew Awuah Wireko, Abdul Qadeer, Alexandra Condurat, Andra Diana Tanasa, Nikolaos Pyrpyris, Kateryna Sikora, Viktoriia Horbas, Aayushi Sood, Rahul Gupta, Carl J Lavie
Personalized medicine has witnessed remarkable progress with the emergence of RNA therapy, offering new possibilities for the treatment of various diseases, and in particular in the context of cardiovascular disease (CVD). The ability to target the human genome through RNA manipulation offers great potential not only in the treatment of cardiac pathologies but also in their diagnosis and prevention, notably in cases of hyperlipidemia and myocardial infarctions. While only a few RNA-based treatments have entered clinical trials or obtained approval from the US Food and Drug Administration, the growing body of research on this subject is promising...
January 20, 2024: Progress in Cardiovascular Diseases